modelG03FA01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | NorethisteroneAndEstrogen | |
| ATC code: | G03FA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 4 | L |
| clearance: | 60 | L/h |
| other parameters in model implementation | ||
Norethisterone and estrogen are combined hormonal preparations used for hormone replacement therapy (HRT) in postmenopausal women and previously also in contraception. Norethisterone is a synthetic progestogen, while estrogen in such combinations is commonly estradiol or ethinylestradiol. These combinations alleviate menopausal symptoms and prevent osteoporosis. Such combined HRT regimens are approved and used in many countries today.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult women after oral administration, based on typical literature values for norethisterone and estradiol or ethinylestradiol separately, as no published studies provide a combined PK model for the combination product.
References
Vose, CW, et al., & Serlin, MJ (1979). Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. Contraception 19(2) 119–127. DOI:10.1016/s0010-7824(79)80024-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/428229
Goldzieher, JW (1990). Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. American journal of obstetrics and gynecology 163(1 Pt 2) 318–322. DOI:10.1016/0002-9378(90)90575-r PUBMED:https://pubmed.ncbi.nlm.nih.gov/2196804
Garza-Flores, J, et al., & Perez-Palacios, G (1991). Long-acting hormonal contraceptives for women. The Journal of steroid biochemistry and molecular biology 40(4-6) 697–704. DOI:10.1016/0960-0760(91)90293-e PUBMED:https://pubmed.ncbi.nlm.nih.gov/1958567
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)